A study evaluating rates of thrombocytopenia among recurrent ovarian cancer patients who initiated niraparib in a real-world US setting
Latest Information Update: 17 Feb 2020
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 17 Feb 2020 New trial record